Evaluation of Hilo® Versus Daflon® in Patients Suffering from Hemorrhoids: A Randomized, Controlled, Open-labelled, Multicentric Study

Main Article Content

Bhupesh Dewan
Sarita Prabhu


Aims: To evaluate and compare the efficacy of Hilo® and Daflon® 500 mg, in the treatment of hemorrhoids.

Study Design: It is a multicentric, randomized, comparative clinical trial conducted for the period of 15 days.

Place and Duration of Study: Janta Hospital and Maternity Centre, Varanasi; King George Memorial Hospital, Lucknow; Vijan Hospital and Research Centre, Nasik and Santosh Hospital, Bangalore between May 2018 and December 2019.

Methodology: 201 patients were screened and 200 patients with hemorrhoids (proctoscopy proven Grade I to III) were randomly assigned to receive either Hilo® capsules (n = 99) or Daflon® 500 mg tablets (n = 101). Assessment of hemorrhoidal symptoms was carried out in all patients on Day 7 and Day 15. Proctoscopic examination was carried out before the start of treatment i.e. on day 0 and at the end of treatment duration i.e. on day 15.

Results: The patients treated with Hilo® showed a statistically significant improvement in the clinical symptoms of bleeding, pain, itching, soiling, tenesmus, irritation after defecation and constipation on day 7 and day 15 as compared to baseline. The “mean total symptom score” reduced by 4.55 ± 2.07 vs 3.44 ± 2.00; P < .0001 on day 7 and 7.56 ± 2.40 vs 6.22 ± 2.55; P < .0001 on day 15 in the patients treated with Hilo® and Daflon® respectively. In Hilo® Group, 82.83% of patients assessed that the treatment with Hilo® made them ‘A lot better’ as compared to only 48.51% in Daflon® group. In the Hilo® group 20.2% of patients’ treatment outcome was assessed as ‘Excellent’ by the investigators as compared to only 0.99% of patients in Daflon® group. No major adverse events were reported in the study with the use of either product.

Conclusion: Hilo® is found to provide better reduction in clinical symptoms of patients suffering from hemorrhoids as compared to Daflon®.

Hemorrhoids, clinical study, phlebotonics, flavonoids, catechins.

Article Details

How to Cite
Dewan, B., & Prabhu, S. (2019). Evaluation of Hilo® Versus Daflon® in Patients Suffering from Hemorrhoids: A Randomized, Controlled, Open-labelled, Multicentric Study. Journal of Advances in Medicine and Medical Research, 30(6), 1-12. https://doi.org/10.9734/jammr/2019/v30i630206
Original Research Article


Lohsiriwat V. Hemorrhoids: From basic pathophysiology to clinical management. World J Gastroenterol. 2012;18(17):2009-2017.
[DOI: 10.3748/wjg. v18.i17.2009]

Gupta A, Mitra SK. Role of piloherb tablets and ointment in the treatment of hemorrhoids. World J Pharm Pharm Sci. 2015;4(8):1640-1647

Sun Z, Migaly J. Review of hemorrhoid disease: Presentation and management. Clin Colon Rectal Surg. 2016;29:22–29.
[PMCID: PMC4755769]
[PMID: 26929748]
DOI: 10.1055/s-0035-1568144]

Mott T, Latimer K, Edwards C. Hemorrhoids: Diagnosis and treatment options. Am Fam Physician. 2018;97(3): 172-179.
[PMID: 29431977]

Wilson MZ, Swarup A, Wilson LRT, Ivatury SJ. The Effect of Nonoperative Management of Chronic Anal Fissure and Hemorrhoid Disease on Bowel Function Patient-Reported Outcomes. Dis Colon Rectum 2018; 61: 1223–1227.
[PMID: 30192331]
DOI: 10.1097/DCR.0000000000001193]
Mayoclinic. Hemorrhoids.
(Accessed 30 April 2019)

Corsale I, Paolo Carrieri P, Martellucci J, Piccolomini A, Verre L, Rigutini M, et al. Flavonoid mixture (Diosmin, troxerutin, rutin, hesperidin, quercetin) in the treatment of I–III degree hemorroidal disease: a double-blind multicenter prospective comparative study. Int J Colorectal Dis; 2018.
[DOI: https://doi.org/10.1007/s00384-018-3102-y]

Perera N, Liolitsa D, Iype S, Croxford A, Yassin M, Lang P, et al. Phlebotonics for hemorrhoids. Cochrane Database Syst Rev. 2012;8.
Art. No.: CD004322.
[PMID: 22895941]
DOI: 10.1002/ 14651858. CD00 4322.pub3]

Danielsson G, Jungbeck C, Peterson K, Norgren L. A randomised controlled trial of micronised purified flavonoid fraction vs placebo in patients with chronic venous disease. Eur J Vasc Endovac Surg. 2002; 23(1):73-6.
[PMID: 11748952]
DOI: 10.1053/ejvs.2001.1531]

Lyseng-Williamson KA, Perry CM. Micronised purified flavonoid fraction. Drugs. 2003;63(1):71-100.

Demir A, Gökakın A, Üreyen O, Altınel Ö, Tezcan E, Gür A, et al. The efficacy of micronized flavonoid fraction (450 mg diosmin plus 50 mg hesperidin) in the treatment of lymphedema after axillary dissection. Cumhuriyet Medical Journal. 2011;33(3):312-7.

Jiang ZM, Cao JD. The impact of micronized purified flavonoid fraction on the treatment of acute haemorrhoidal episodes. Curr Med Res Opin. 2006; 22(6):1141-7.
[PMID: 16846547]
DOI: 10.1185/030079906X104803]

Pascarella L, Lulic D, Penn AH, Alsaigh T, Lee J, Shin H, et al. Mechanisms in experimental venous valve failure and their modification by Daflon® 500 mg. Eur J Vasc Endovasc Surg. 2008;35:102e110.
DOI: 10.1016/j.ejvs.2007.08.011]

ICH Harmonised Guideline Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2) Current Step 4; 2016.

Schedule Y (Ammended version 2005) Drugs and Cosmetics Rules. CDSCO; 1945.

MacKay D, Candidate ND. Hemorrhoids and Varicose Veins: A review of treatment options. Altern Med Rev. 2001;6(2):126-140.

Mlakar B, Kosorok P. Flavonoids to reduce bleeding and pain after stapled hemorrhoidopoxy: A randomised controlled trial. Wien Klin Wochenchr. 2005;115/14-16:558-560.
[DOI: 10.1007/s00508-005-0420-1]

Aggrawal K, Satija N, Dasgupta G, Dasgupta P, Nain P, Sahu AR. Efficacy of a standardized herbal preparation (Roidosanal®) in the treatment of hemorrhoids: A randomized, controlled, open-label multicentre study. Journal of Ayurveda & Integrative Medicine. 2014; 5(2):117-14.